J.Jpn. Surg. Soc.. 83(8): 769-782, 1982

---

Original article

EFFECT OF MIZORIBINE ON CANINE KIDNEY ALLOGRAFT SURVIVAL IN COMPARISON WITH THE CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY

Mizoribine (4-carbamoyl-1-β-D-ribofuranosyl-imidazolium-5-olate) (MZ) is a new immunosuppressive drug. The aim of this study was to test the immunosuppressive effectiveness of MZ on canine kidney allograft survival and to determine the side effects, if any, of the drug. Moreover, the effectiveness of MZ was compared with those of other conventional immunosuppressive agents, azathioprine (AZ) and prednisolone (PR).
Results :
1) A dose-dependent prolongation of the allograft survival was observed by MZ administration.
Maximal mean survival period (34.7±4.9days) was obtained when 5.0mg/kg/day of MZ treatment was instituted.
2) No abnormalities in transaminase or decreases in WBC count were observed at any dose of MZ (2.5-10.0mg/kg/ day).
3) Histologically, general architectures of the grafts treated with MZ were well preserved, but a more remarkable infiltration of mononuclear cells around the glomeruli or vessels was noted, compared with grafts treated with AZ.
4) Maximal graft survivals were obtained when 2.5mg/kg/day of AZ was given, although the grafted animals developed remarkable bone marrow depression.
5) By adding AZ and/or PR, the survival-prolonging effect of MZ was strengthened synergistically.
From the survival of recipient animals and histological findings of the grafts, the best results were obtained by combined treatment with MZ, AZ and PR. Therefore, the triple drug treatment will be advivable for clinical renal transplantation.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.